1. Global Lung Function Initiative reference values for multiple breath washout indices.
- Author
-
Ramsey KA, Stanojevic S, Chavez L, Johnson N, Bowerman C, Hall GL, Latzin P, O'Neill K, Robinson PD, Stahl M, Weiner DJ, Zwitserloot AM, and Horsley A
- Subjects
- Humans, Male, Female, Reference Values, Aged, Middle Aged, Adult, Functional Residual Capacity physiology, Aged, 80 and over, Young Adult, Adolescent, Child, Child, Preschool, Healthy Volunteers, Breath Tests instrumentation, Breath Tests methods, Tidal Volume physiology, Respiratory Function Tests standards, Respiratory Function Tests instrumentation, Lung physiology
- Abstract
Background: Multiple breath washout is a lung function test based on tidal breathing that assesses lung volume and ventilation distribution. The aim of this analysis was to use the Global Lung Function Initiative methodology to develop all-age reference equations for the multiple breath washout indices lung clearance index (LCI) and functional residual capacity (FRC)., Methods: Multiple breath washout data from healthy individuals were collated from sites. Data were re-analysed using the latest software versions. Reference equations were derived using the lambda-mu-sigma method using the generalised additive models of location shape and scale programme in R. The impact of equipment type, inert tracer gas and equipment dead space volume on the derived reference ranges were investigated., Results: Data from 23 sites (n=3647 test occasions) were submitted. Reference equations were derived from 1579 unique observations from participants between the ages of 2 and 81 years. Equipment type, inert tracer gas and equipment dead space volume did not significantly affect the prediction equations for either LCI or FRC. Reference equations for LCI include age as the only predictor, whereas sex-specific reference equations for FRC included height and age., Conclusions: Global Lung Function Initiative reference equations for multiple breath washout variables provide a standard for reporting and interpretation of LCI and FRC., Competing Interests: Conflict of interest: K.A. Ramsey reports support for the present study from ERS. S. Stanojevic reports grants from ATS, consultancy fees from Chiesi Farmaceuticals, payment or honoraria for lectures, presentations, manuscript writing or educational events from Vyaire Medical, participation on a data safety monitoring board or advisory board with Ndd Technologies, leadership roles with ATS (Pulmonary Function Testing Committee) and ERS (Global Lung Function Initiative), and the following financial (or non-financial) interests: Statistical Editor at Thorax, Editorial Board Member at European Respiratory Journal, and Junior Associate Editor at Canadian Journal of Respiratory, Critical Care and Sleep Medicine. C. Bowerman reports grants from Canadian Lung Association, support for attending meetings from Canadian Thoracic Society, and leadership role with Global Lung Function Initiative (Junior Executive). G.L. Hall reports support for the present study from ERS, as co-chair of the Global Lung Function Initiative. P. Latzin reports grants from Vertex and OM Pharma, payment or honoraria for lectures, presentations, manuscript writing or educational events from Vertex, Vifor and OM Pharma, and participation on a data safety monitoring board or advisory board with Polyphor, Santhera (DMC), Vertex, OM Pharma, Vifor, Allecra and Sanofi Aventis. M. Stahl reports support for the present study from German Research Foundation (Deutsche Forschungsgemeinschaft, DFG), grants, payment or honoraria for lectures, presentations, manuscript writing or educational events and participation on a data safety monitoring board or advisory board with Vertex Pharmaceuticals, and leadership roles with FGM (Chairman), ERS (Secretary Group CF), and GPP (Treasurer). D.J. Weiner reports consultancy fees from Cystic Fibrosis Foundation. A.M. Zwitserloot reports grants from Vertex Pharmaceuticals, and consultancy fees from Sanofi. A. Horsley reports support for the present study from ERS, grants from NIHR Manchester Biomedical Research Centre, consultancy fees, payment or honoraria for lectures, presentations, manuscript writing or educational events, and receipt of equipment, materials, drugs, medical writing, gifts or other services from Vertex Pharmaceuticals, a leadership role with NIHR Respiratory Translational Research Collaboration (Chair), and technical support provided to Innocor ApS. The remaining authors have no potential conflicts of interest to disclose., (Copyright ©The authors 2024. For reproduction rights and permissions contact permissions@ersnet.org.)
- Published
- 2024
- Full Text
- View/download PDF